NCT07092605View on ClinicalTrials.gov

Effectiveness of Microdosed GLP-1 in Improving Health, Quality of Life, and Longevity Measures

EARLY_PHASE1Enrolling by invitationINTERVENTIONAL
Enrollment

150

Participants

Timeline

Start Date

November 1, 2024

Primary Completion Date

November 1, 2025

Study Completion Date

December 1, 2025

Conditions
LongevityQuality of LifeMoodInflammationImmune HealthPain ManagementWeight ManagementAlertness
Interventions
DRUG

GLP-1

Sublingual GLP1 (weekly), Subcutaneous GLP1 (weekly), Sublingual Placebo (weekly) for up to 6 months.

DRUG

Placebo

Sublingual Placebo (weekly) for up to 6 months

Trial Locations (1)

48104

AgelessRx, Ann Arbor

Sponsors

Lead Sponsor

AgelessRx
All Listed Sponsors
lead

AgelessRx

INDUSTRY

NCT07092605 - Effectiveness of Microdosed GLP-1 in Improving Health, Quality of Life, and Longevity Measures | Biotech Hunter | Biotech Hunter